These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 15558054)

  • 1. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors.
    Issaeva N; Bozko P; Enge M; Protopopova M; Verhoef LG; Masucci M; Pramanik A; Selivanova G
    Nat Med; 2004 Dec; 10(12):1321-8. PubMed ID: 15558054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro.
    Burmakin M; Shi Y; Hedström E; Kogner P; Selivanova G
    Clin Cancer Res; 2013 Sep; 19(18):5092-103. PubMed ID: 23864164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting MDM2 by the small molecule RITA: towards the development of new multi-target drugs against cancer.
    Espinoza-Fonseca LM
    Theor Biol Med Model; 2005 Sep; 2():38. PubMed ID: 16174299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The p53-reactivating small-molecule RITA enhances cisplatin-induced cytotoxicity and apoptosis in head and neck cancer.
    Roh JL; Ko JH; Moon SJ; Ryu CH; Choi JY; Koch WM
    Cancer Lett; 2012 Dec; 325(1):35-41. PubMed ID: 22634494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abrogation of Wip1 expression by RITA-activated p53 potentiates apoptosis induction via activation of ATM and inhibition of HdmX.
    Spinnler C; Hedström E; Li H; de Lange J; Nikulenkov F; Teunisse AF; Verlaan-de Vries M; Grinkevich V; Jochemsen AG; Selivanova G
    Cell Death Differ; 2011 Nov; 18(11):1736-45. PubMed ID: 21546907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA.
    Jones RJ; Bjorklund CC; Baladandayuthapani V; Kuhn DJ; Orlowski RZ
    Mol Cancer Ther; 2012 Oct; 11(10):2243-53. PubMed ID: 22933706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer drug discovery: the wisdom of imprecision.
    Gudkov AV
    Nat Med; 2004 Dec; 10(12):1298-9. PubMed ID: 15580251
    [No Abstract]   [Full Text] [Related]  

  • 8. RITA enhances chemosensivity of pre-B ALL cells to doxorubicin by inducing p53-dependent apoptosis.
    Kazemi A; Safa M; Shahbazi A
    Hematology; 2011 Jul; 16(4):225-31. PubMed ID: 21756539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-specific induction of apoptosis by a p53-reactivating compound.
    Hedström E; Issaeva N; Enge M; Selivanova G
    Exp Cell Res; 2009 Feb; 315(3):451-61. PubMed ID: 19071110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA.
    Zhao CY; Grinkevich VV; Nikulenkov F; Bao W; Selivanova G
    Cell Cycle; 2010 May; 9(9):1847-55. PubMed ID: 20436301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface.
    Chène P
    Mol Cancer Res; 2004 Jan; 2(1):20-8. PubMed ID: 14757842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53.
    Higashitsuji H; Higashitsuji H; Itoh K; Sakurai T; Nagao T; Sumitomo Y; Masuda T; Dawson S; Shimada Y; Mayer RJ; Fujita J
    Cancer Cell; 2005 Jul; 8(1):75-87. PubMed ID: 16023600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting p53 via JNK pathway: a novel role of RITA for apoptotic signaling in multiple myeloma.
    Saha MN; Jiang H; Yang Y; Zhu X; Wang X; Schimmer AD; Qiu L; Chang H
    PLoS One; 2012; 7(1):e30215. PubMed ID: 22276160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
    Lau LM; Nugent JK; Zhao X; Irwin MS
    Oncogene; 2008 Feb; 27(7):997-1003. PubMed ID: 17700533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mdm2-P53 Interaction Inhibitor with Cisplatin Enhances Apoptosis in Colon and Prostate Cancer Cells In-Vitro.
    Gupta A; Behl T; Heer HR; Deshmukh R; Sharma PL
    Asian Pac J Cancer Prev; 2019 Nov; 20(11):3341-3351. PubMed ID: 31759358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutated and non-mutated TP53 as targets in the treatment of leukaemia.
    Nahi H; Selivanova G; Lehmann S; Möllgård L; Bengtzen S; Concha H; Svensson A; Wiman KG; Merup M; Paul C
    Br J Haematol; 2008 May; 141(4):445-53. PubMed ID: 18341636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IGF-1R/MDM2 relationship confers enhanced sensitivity to RITA in Ewing sarcoma cells.
    Di Conza G; Buttarelli M; Monti O; Pellegrino M; Mancini F; Pontecorvi A; Scotlandi K; Moretti F
    Mol Cancer Ther; 2012 Jun; 11(6):1247-56. PubMed ID: 22461661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RITA can induce cell death in p53-defective cells independently of p53 function via activation of JNK/SAPK and p38.
    Weilbacher A; Gutekunst M; Oren M; Aulitzky WE; van der Kuip H
    Cell Death Dis; 2014 Jul; 5(7):e1318. PubMed ID: 25010984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficient synthesis of RITA and its analogues: derivation of analogues with improved antiproliferative activity via modulation of p53/miR-34a pathway.
    Lin J; Jin X; Bu Y; Cao D; Zhang N; Li S; Sun Q; Tan C; Gao C; Jiang Y
    Org Biomol Chem; 2012 Dec; 10(48):9734-46. PubMed ID: 23151607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
    Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
    Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.